Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Astellas Pharma Inc. (TSE: ...

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious ...

Gene therapy developers rely on engineered viruses to carry genetic cargo to cells. Adeno-associated virus, the viral vector that has been the backbone of this burgeoning field, shows a particular ...

Novartis has already commercialized a gene therapy that targets the central nervous system, but the pharmaceutical giant has more CNS gene therapies in its pipeline and it’s looking to improve the way ...

(RTTNews) - Voyager Therapeutics, Inc. (VYGR), a developer of adeno-associated virus or AAV capsids, announced Tuesday a license option agreement, under which Novartis (NVS) will receive ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...

Joseph La Barge has been mulling over the limitations of gene therapy for some time. So, when he left his position at Spark Therapeutics, having watched the company grow from its start in borrowed ...

- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data ...

The possibilities for gene therapies are being realized as candidates come to market with hundreds more in development. Adeno-associated virus (AAV) is a common vector, yet current production, ...

In viral capsids, T=3 and T=4 refer to the triangulation number, a value that describes how protein subunits are arranged to build a larger, stable, icosahedral structure. A higher number corresponds ...